Results 161 to 170 of about 6,869 (208)
Some of the next articles are maybe not open access.
Infectious Diseases in Clinical Practice, 2005
Anidulafungin (LY-303366, VER002) is a semisynthetic derivative of echinocandin B and a potent antifungal agent active against a wide spectrum of fungal pathogens. We reviewed published papers, abstracts, and data to provide an overview focusing on the microbiology of anidulafungin and its promise for treating fungal infections. Anidulafungin was found
Mahmoud Ghannoum, Maurissa D'Angelo
openaire +1 more source
Anidulafungin (LY-303366, VER002) is a semisynthetic derivative of echinocandin B and a potent antifungal agent active against a wide spectrum of fungal pathogens. We reviewed published papers, abstracts, and data to provide an overview focusing on the microbiology of anidulafungin and its promise for treating fungal infections. Anidulafungin was found
Mahmoud Ghannoum, Maurissa D'Angelo
openaire +1 more source
Expert Opinion on Drug Safety, 2006
The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi.
openaire +2 more sources
The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi.
openaire +2 more sources
Hospital Pharmacy, 2006
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +1 more source
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +1 more source
Anidulafungin-Induced Alopecia
Annals of Pharmacotherapy, 2014Objetive: To report a case of a woman in whom alopecia appeared after several months of treatment with anidulafungin. Case Summary: A 34-year-old woman with chronic femoral osteomyelitis with the presence of persistent suppuration, developed a Candida albicans infection, isolated in the fistula exudate cultures. After initial failures of single therapy
Ruiz-Ramos J +5 more
openaire +3 more sources
IDrugs : the investigational drugs journal, 2004
Anidulafungin, a 1,3-beta-glucan synthesis inhibitor and the pentyloxyterphenyl side chain derivative of echinocandin B, is being developed by Vicuron Pharmaceuticals Inc, under license from Eli Lilly & Co, for the potential treatment of fungal infection.
openaire +2 more sources
Anidulafungin, a 1,3-beta-glucan synthesis inhibitor and the pentyloxyterphenyl side chain derivative of echinocandin B, is being developed by Vicuron Pharmaceuticals Inc, under license from Eli Lilly & Co, for the potential treatment of fungal infection.
openaire +2 more sources